scholarly journals RET Rearrangement Analysis Was Performed

2020 ◽  
Author(s):  
Keyword(s):  
Ret Rearrangement

Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma

2021 ◽  
Vol 109 ◽  
pp. 37-44
Author(s):  
Hidetaka Yamamoto ◽  
Yui Nozaki ◽  
Azusa Sugii ◽  
Kenichi Taguchi ◽  
Takahiro Hongo ◽  
...  
Keyword(s):  
Receptor Kinase ◽  
Secretory Carcinoma ◽  
Ret Rearrangement

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Lung Cancer ◽  
2015 ◽  
Vol 89 (3) ◽  
pp. 357-359 ◽  
Author(s):  
Samuel J. Klempner ◽  
Lyudmila A. Bazhenova ◽  
Fadi S. Braiteh ◽  
Petros G. Nikolinakos ◽  
Kyle Gowen ◽  
...  
Keyword(s):  
Second Generation ◽  
Egfr Mutation ◽  
Ret Rearrangement ◽  
Nsclc Patients ◽  
Egfr Mutated ◽  
Egfr Tki

scholarly journals RASAL2-RET: a novel RET rearrangement in a patient with high-grade sarcoma of the chest

2020 ◽  
Vol 31 (5) ◽  
pp. 659-661
Author(s):  
Y. Zhou ◽  
C. Qi ◽  
M.Z. Xiao ◽  
S.L. Cai ◽  
B.J. Chen
Keyword(s):  
High Grade ◽  
High Grade Sarcoma ◽  
Ret Rearrangement

scholarly journals KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease

2017 ◽  
Vol 102 (9) ◽  
pp. 3091-3096 ◽  
Author(s):  
David Viola ◽  
Carlotta Giani ◽  
Salvatore Mazzeo ◽  
Clara Ugolini ◽  
Raffaele Ciampi ◽  
...  
Keyword(s):  
Case Report ◽  
Thyroid Gland ◽  
Fatal Disease ◽  
Ret Rearrangement

scholarly journals RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

2020 ◽  
Vol 8 (2) ◽  
pp. 333-339 ◽  
Author(s):  
Sara Baglivo ◽  
Vienna Ludovini ◽  
Riccardo Moretti ◽  
Guido Bellezza ◽  
Angelo Sidoni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Ret Rearrangement

Clinical outcomes of NSCLC patients with acquired RET rearrangement after resistance to osimertinib.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20626-e20626
Author(s):  
Chang Lu ◽  
Jia-Tao Cheng ◽  
Jin Kang ◽  
Yi-Hui Yao ◽  
Xiang-Meng Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcomes ◽  
Acquired Resistance ◽  
Progression Free Survival ◽  
Best Supportive Care ◽  
Line Treatment ◽  
Significant Difference ◽  
Ret Rearrangement ◽  
Egfr Mutant

e20626 Background: Resistance mechanisms to osimertinib have raised growing concerns, but those with acquired RET rearrangement is poorly characterized. Methods: We retrospectively identified advanced, EGFR-mutant NSCLC (non-small-cell lung cancer) patients treated with osimertinib between April 9th, 2015 and November 1st, 2018 at our institute. Clinicopathologic features and clinical outcomes were analyzed. Subsequent genetic profiling was performed at the time of progression by next-generation sequencing (NGS). Overall survival (OS) since 1st line treatment was calculated from first-line treatment start to death or last follow up, and OS post-progression was calculated from osimertinib progression. Median follow-up time was 43.4 months. Results: In the 192 patients treated with osimertinib, 57 had follow-up NGS information after progression, and six harboured acquired RET rearrangement (11%, 6/57). For patients with RET rearrangements when progressed on osimertinib, OS since 1st line treatment (22.9m vs 59.5m, P = 0.021) and OS post-progression (2.1m vs 10.0m, P = 0.031) were significantly shorter compared with non- RET-rearranged cases, whereas no significant difference was found in demographics at the initial lung cancer diagnosis or progression-free survival (PFS) of osimertinib (12.1m vs 5.8m, P = 0.34). Among these six patients, one received best supportive care, two continued to use drugs targeting EGFR but deteriorating soon, three patients tried osimertinib combined with cabozantinib with one benefit from this combination approach. Conclusions: RET rearrangements could exist in EGFR-mutant NSCLC with acquired resistance to osimertinib and linked to inferior survival. Study on the molecular evolution and heterogeneity during treatment course are warranted for further therapeutic strategies. [Table: see text]

National Comprehensive Cancer Network petitions: Submissions and outcomes.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 248-248
Author(s):  
Laura Bobolts ◽  
Dinah Faith Huff ◽  
William J. Hrushesky ◽  
Charles Lee Bennett ◽  
Kevin Knopf ◽  
...  
Keyword(s):  
Supportive Care ◽  
National Comprehensive Cancer Network ◽  
Liposomal Doxorubicin ◽  
Scientific Literature ◽  
Nccn Guidelines ◽  
Fda Approval ◽  
Her 2 ◽  
Ret Rearrangement ◽  
Cancer Network ◽  
Japanese Ancestry

248 Background: The National Comprehensive Cancer Network (NCCN) invites petitions to its scientific panels. Most ( > 95%) are from the pharmaceutical industry lobbying to include their products in the NCCN Guidelines. Rarely, physicians request scientific scrutiny of the guidelines. We report the experience of Oncology Analytics (OA) with petition submissions and the possible impact on guidelines. Methods: From 2011-2015, OA made 7 petitions to NCCN. The content of each was tracked into subsequent NCCN Guidelines to ascertain whether any changes resulted. Results: 1) The Survivorship Panel was petitioned to add liposomal doxorubicin to the list of cardiotoxic anthracyclines: No changes were made. 2-3) The NSCLC Panel was asked in 2014 to remove the category 2A listing for trastuzumab and afatinib as HER-2 targeted drugs, and cabozantinib as a RET rearrangement target based on absence of phase I-III full text scientific literature. This was done, however, cabozantinib was reverted to 2A status late 2015 based on abstract-only data. 4) Per FDA approval, the NSCLC Panel was asked to recommend bevacizumab only in combination with carboplatin/paclitaxel for 1st line non-squamous NSCLC based on a survival advantage in ECOG 4599: No changes were made. 5) Given the FDA-approval, the Ovarian Cancer Panel was requested to add doxorubicin: This was done. 6) A 2012 Supportive Care Panel petition pointed out the absence of data supporting palonosetron as the preferred 5-HT3 antagonist with aprepitant for moderate or high emetic risk chemotherapy: No change was made upon request; however, preferred status was removed in 2015 from high emetic risk. 7) Based on a preponderance of evidence, a Supportive Care Panel petition requested re-categorization of the febrile neutropenia risk for carboplatin/paclitaxel from intermediate to low except in patients of Japanese ancestry and/or carboplatin AUC > 6: This was done. Conclusions: Majority of NCCN physician petitions came from OA, yet constituted less than 5% of all petitions submitted. NCCN does not provide direct petitioner feedback, so we cannot say for certain that our petitions led to changes in subsequent guidelines. Not all requests resulted in NCCN changes, despite level one supportive data or accentuating an absence of data.

Sign in / Sign up

Export Citation Format

Share Document